Table 2 Characteristics of studies included in this meta-analysis
Study, year | Country | Duration | Sample size | Median follow-up (months) | cancer type | Stage | Treatment | Study design | Survival outcome | Cut-off | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|
Guo 2017 | China | 2010–2011 | 189 | 45 | BC | Mixed | Surgery | R | OS | 3 | 7 |
Miyake 2017 | Japan | 2006–2016 | 117 | NR | BC | Non-metastatic | Surgery | R | OS,CSS | 1 | 8 |
Zhang 2019 | Chian | 2015–2017 | 94 | 16.31 | PC | Metastatic | Surgery | R | PFS | 3 | 7 |
Elghiaty 2019 | Egypt | 2005–2014 | 1046 | 63 | RCC | Non-metastatic | Surgery | R | OS,CSS,RFS | 2 | 8 |
Kang 2018 1 | Korean | 1999–2015 | 1418 | 41 | RCC | Mixed | Surgery | R | CSS | 2 | 7 |
Kang 2018 2 | Korean | 1999–2015 | 1282 | 41 | RCC | Non-metastatic | Surgery | R | RFS | 2 | 7 |
Song 2019 | China | 2010–2012 | 325 | 64 | RCC | Non-metastatic | Surgery | R | OS,CSS,DFS | 3 | 8 |
Takemura 2020 | Japan | 2016–2019 | 49 | 26.4 | RCC | Metastatic | Target therapy | R | CSS,PFS | 2 | 7 |
Zheng 2018 | China | 2004–2014 | 635 | 48.4 | RCC | Non-metastatic | Surgery | R | OS,CSS | 2 | 8 |
Ishihara 2017 | Japan | 2003–2014 | 107 | Mean: 41.48 | UTUC | Non-metastatic | Surgery | R | OS,CSS,RFS | 3 | 7 |
Xu 2018 | China | 2004–2016 | 572 | 41 | UTUC | Mixed | Surgery | R | OS,CSS,RFS | 2 | 8 |
Bao 2020 | China | 1999–2015 | 408 | 32 | UTUC | Non-metastatic | Surgery | R | OS,CSS,DFS | 3 | 8 |
Suzuki 2020 | Japan | 2003–2018 | 163 | 12.3 | UC | Metastatic | Mixed | R | OS | 2 | 8 |